Core Insights - The independent data and safety monitoring board (DSMB) has recommended the continuation of the Phase 3 EFZO-FIT™ study of efzofitimod without any modifications, indicating no safety concerns [1][2] - The study aims to position efzofitimod as a potential chronic maintenance therapy for pulmonary sarcoidosis, with topline results expected in Q3 2025 [2] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The lead therapeutic candidate, efzofitimod, is being investigated for its efficacy and safety in treating pulmonary sarcoidosis and other interstitial lung diseases (ILD) [3][4] Study Details - The EFZO-FIT™ study is a global Phase 3 randomized, double-blind, placebo-controlled trial involving 268 subjects, assessing the efficacy of efzofitimod administered intravenously at doses of 3.0 mg/kg or 5.0 mg/kg [2][3] - The primary endpoint is steroid reduction, while secondary endpoints include lung function and sarcoidosis symptoms [2]
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis